Ashwagandha (Withania somnifera) and Chronic Kidney Disease: Latest Research 2026

By Insight Swarm Research Team, Medical Advisor: Nikhil Joshi, MD, FRCPC

Ashwagandha (Withania somnifera) and Chronic Kidney Disease: Latest Research 2026

This page summarizes the current state of scientific research on Ashwagandha (Withania somnifera) in the context of Chronic Kidney Disease as of 2026. The field evolves rapidly — this is a research summary, not medical advice. Consult your nephrologist for personalized guidance.

Compound Overview

Ashwagandha (Withania somnifera) (Adaptogen / Herbal) — Dietary supplement; not FDA-approved

Mechanism of action: HPA axis modulation; reduces cortisol; GABAergic activity; Nrf2 activation; anti-inflammatory withanolides

Current evidence level: Multiple RCTs for stress/anxiety; some thyroid and testosterone data; cancer data preclinical

2026 Research Landscape

Direct research on Ashwagandha (Withania somnifera) specifically for CKD remains limited as of 2026, though the mechanistic connections continue to be explored in laboratory settings.

Key areas researchers are currently examining include:

  • Mechanistic studies: Understanding precisely how Ashwagandha (Withania somnifera) affects the biological pathways involved in Chronic Kidney Disease progression
  • Safety characterization: Defining appropriate doses and monitoring protocols if clinical use is considered
  • Biomarker identification: Finding measurable indicators that could predict which patients might respond
  • Screening studies: Preclinical models are still being used to establish whether clinical investigation is warranted

Where to Find the Most Current Research

To access the latest peer-reviewed publications:

  • PubMed: Search "(Ashwagandha (Withania somnifera)[tiab]) AND (Chronic Kidney Disease[tiab])" at pubmed.ncbi.nlm.nih.gov
  • ClinicalTrials.gov: Search for active and completed trials with Ashwagandha (Withania somnifera) keywords
  • Google Scholar: Sort by date for most recent publications

Research Gaps

The most significant gaps in the Ashwagandha (Withania somnifera) + CKD research landscape as of 2026 include: lack of large Phase III randomized trials, limited long-term safety data in CKD patients, and absence of biomarker-selected patient populations who might benefit most.

Medical Disclaimer: This page summarizes published research and is not medical advice. Never start, stop, or change any treatment based on information found online. Always consult qualified healthcare professionals before making treatment decisions.

Get a personalized AI-generated research report at insightswarm.ai.

Frequently Asked Questions

What are the most recent studies on Ashwagandha (Withania somnifera) for CKD?

The most current peer-reviewed studies can be found on PubMed (pubmed.ncbi.nlm.nih.gov). Search for 'Ashwagandha (Withania somnifera) Chronic Kidney Disease' filtered to the last 2 years. The current evidence level is: Multiple RCTs for stress/anxiety; some thyroid and testosterone data; cancer data preclinical.

Are there any 2025-2026 clinical trials for Ashwagandha (Withania somnifera) in CKD?

Check ClinicalTrials.gov with 'Ashwagandha (Withania somnifera)' as intervention and 'Chronic Kidney Disease' as condition. Filter by 'Recruiting' status for currently enrolling trials. Your nephrologist can advise whether any trials may be appropriate for your specific situation.

Has the evidence for Ashwagandha (Withania somnifera) in CKD changed recently?

The field evolves rapidly. The current evidence classification is: Multiple RCTs for stress/anxiety; some thyroid and testosterone data; cancer data preclinical. For the most up-to-date summary, Insight Swarm generates personalized research reports that incorporate the latest publications specific to your case.